[Federal Register Volume 63, Number 210 (Friday, October 30, 1998)]
[Notices]
[Pages 58404-58405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-29072]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

[[Page 58405]]

Cannabinoids As Neuroprotectants

A Hampson, J Axelrod, M Grimaldi (NIMH)
DHHS Reference Nos. E-287-97/0 filed 21 Apr 98 and E-287-97/1 filed 10 
Aug 98
Licensing Contact: Stephen Finley, 301/496-7735 ext. 215

    This technology describes the neuroprotective properties of 
cannabidiol (CBD), 2-[3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1y1]-5-
pentyl-1,3-benzenediol. Cannabidiol is a neuroprotective cannabinoid 
that does not possess the psychoactive qualities which have previously 
hampered the development of cannabinoid-based therapeutics. Cannabidiol 
is an effective blood-brain barrier permeable antioxidant, that is more 
potent than either tocopherol or ascorbate. As reported in PNAS 95, 
8268-73 (July 1998), CBD can protect neurons from both glutamate and 
free radical induced toxicity. It is believed that CBD may present a 
viable alternative for treatment of ischemia or physical traumas. This 
technology is currently available for either licensing or collaborative 
efforts under a Cooperative Research and Development Agreement (CRADA).

Methods and Compositions for Inhibiting Inflammation and 
Angiogenesis

K Kelly (NCI)
PCT/US97/19772 filed 24 Oct 97 (claiming priority of USSN 60/027,871 
filed 25 Oct 96)
Licensing Contact: Charles Maynard, 301/496-7735 ext. 243

    The invention provides compositions and methods directed to 
isolated  subunits of the 7TM protein CD97. CD97 is a 
heterodimer existing in three isoforms, namely three forms of  
subunit and one invariant  subunit. The invention provides 
compositions and methods for detecting a subunit of CD97, a T-cell 
protein which is upregulated in activated T-cells and is involved in 
the onset and maintenance of inflammation and angiogenesis. The 
invention provides an isolated protein comprising a soluble CD97 
 subunit, and an isolated nucleic acid encoding a soluble CD97 
 subunit protein. The invention also provides methods for 
identifying compounds which inhibit soluble CD97  subunit 
expression. The invention may be used to inhibit angiogenesis 
associated with chronic inflammation in a mammal by administering a 
therapeutically effective amount of a CD97 antagonist. Another 
application includes determining the degree of inflammation at a site 
in a mammal with an antibody composition specifically reactive to a 
soluble CD97  subunit. Further, it should be noted that these 
compositions and methods have in vitro utility in the construction of 
proteins and subsequences thereof for the construction of antibodies, 
and nucleic acids and subsequences thereof for use as probes.

Genetic Polymorphisms Of Interleukin-1 Alpha And Beta Associated 
With Early Onset Periodontitis

SR Diehl, HA Schenkein, YF Wang (NIDR)
Serial No. 09/035,220 filed 05 Mar 97
Licensing Contact: Dennis Penn, 301/496-7056 ext. 211

    Periodontal disease occurs in 10-20% of adults, and constitutes a 
major cause of tooth loss. About 0.5% of U.S. adolescents between the 
ages of 14 to 17 years old (about 70,000) have localized early onset 
periodontitis and 0.1% (17,000) have the more destructive form known as 
generalized early onset periodontitis. Both types of early onset 
periodontitis often lead to tooth loss before the age of 20. 
Extrapolation of these figures up to age 35 leads to estimates of early 
onset periodontitis having a major impact on the dental health of 
400,000 individuals in the U.S. population. Discovery of genetic 
polymorphisms at the interleukin 1 alpha and 1 beta genes significantly 
associated with disease risk allows genetic testing to be used to 
predict disease prior to onset. This can be used to target clinical 
efforts for disease prevention to those individuals at greatest risk. 
The genetic test can also justify more aggressive therapeutic 
treatments for individuals already affected by the early onset 
periodontitis who, based on their genetic profile, are predicted to 
exhibit very rapid disease progression.

    Dated: October 24, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 98-29072 Filed 10-29-98; 8:45 am]
BILLING CODE 4140-01-M